Literature DB >> 19903104

Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program.

Daniel J Powell1, Andrea L Brennan, Zhaohui Zheng, Hong Huynh, Julio Cotte, Bruce L Levine.   

Abstract

BACKGROUND AIMS: Clinical-scale lymphocyte enrichment from a leukapheresis product has been performed most routinely using costly magnetic bead separation systems that deplete monocytes, but this procedure may leave behind residual beads or antibodies in the enriched cell product. Counterflow centrifugal elutriation has been demonstrated previously to enrich monocytes efficiently for generation of dendritic cells. This study describes a modified elutriation procedure for efficient bead-free economical enrichment of lymphocytes from leukapheresis products from healthy donors and study subjects with human immunodeficiency virus (HIV) infection or malignancy.
METHODS: Modified program settings and conditions for the CaridianBCT Elutra device were investigated to optimize lymphocyte enrichment and recovery. Lymphocyte enrichment was measured using a novel approach utilizing cell sizing analysis on a Beckman Coulter Multisizer and confirmed by flow cytometry phenotypic analysis.
RESULTS: Efficient enrichment and recovery of lymphocytes from leukapheresis cell products was achieved using modified elutriation settings for flow rate and fraction volume. Elutriation allowed for enrichment of larger numbers of lymphocytes compared with depletion of monocytes by bead adherence, with a trend toward increased lymphocyte purity and yield via elutriation, resulting in a substantial reduction in the cost of enrichment per cell. Importantly, significant lymphocyte enrichment could be accomplished using leukapheresis samples from healthy donors (n=12) or from study subjects with HIV infection (n=15) or malignancy (n=12).
CONCLUSIONS: Clinical-scale closed-system elutriation can be performed efficiently for the selective enrichment of lymphocytes for immunotherapy protocols. This represents an improvement in cost, yield and purity over current methods that require the addition of monocyte-depleting beads.

Entities:  

Mesh:

Year:  2009        PMID: 19903104     DOI: 10.3109/14653240903188921

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  13 in total

1.  Identification and isolation of small CD44-negative mesenchymal stem/progenitor cells from human bone marrow using elutriation and polychromatic flow cytometry.

Authors:  Sean R R Hall; Yajuan Jiang; Elizabeth Leary; Greg Yavanian; Sarah Eminli; David W O'Neill; Wayne A Marasco
Journal:  Stem Cells Transl Med       Date:  2013-07-11       Impact factor: 6.940

Review 2.  Engineered T cells: the promise and challenges of cancer immunotherapy.

Authors:  Andrew D Fesnak; Carl H June; Bruce L Levine
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

Review 3.  Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells.

Authors:  B L Levine
Journal:  Cancer Gene Ther       Date:  2015-02-13       Impact factor: 5.987

Review 4.  CAR-T Cell Therapies From the Transfusion Medicine Perspective.

Authors:  Andrew Fesnak; ChieYu Lin; Don L Siegel; Marcela V Maus
Journal:  Transfus Med Rev       Date:  2016-03-28

5.  Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.

Authors:  Dawn A Maier; Andrea L Brennan; Shuguang Jiang; Gwendolyn K Binder-Scholl; Gary Lee; Gabriela Plesa; Zhaohui Zheng; Julio Cotte; Carmine Carpenito; Travis Wood; S Kaye Spratt; Dale Ando; Philip Gregory; Michael C Holmes; Elena E Perez; James L Riley; Richard G Carroll; Carl H June; Bruce L Levine
Journal:  Hum Gene Ther       Date:  2013-03-06       Impact factor: 5.695

Review 6.  Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy.

Authors:  Andrew D Fesnak; Patrick J Hanley; Bruce L Levine
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

Review 7.  Current translational and clinical practices in hematopoietic cell and gene therapy.

Authors:  David L Digiusto; Hans-Peter Kiem
Journal:  Cytotherapy       Date:  2012-08       Impact factor: 5.414

8.  Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.

Authors:  David F Stroncek; Jiaqiang Ren; Daniel W Lee; Minh Tran; Sue Ellen Frodigh; Marianna Sabatino; Hanh Khuu; Melinda S Merchant; Crystal L Mackall
Journal:  Cytotherapy       Date:  2016-05-17       Impact factor: 5.414

9.  Hurdles Associated with the Translational Use of Genetically Modified Cells.

Authors:  Sunil S Raikar; H Trent Spencer
Journal:  Curr Stem Cell Rep       Date:  2018-02-17

10.  A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.

Authors:  Lana E Kandalaft; Daniel J Powell; George Coukos
Journal:  J Transl Med       Date:  2012-08-03       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.